| scholarly article | Q13442814 |
| P50 | author | National Cardiovascular Data Registry | Q59977286 |
| Eric D. Peterson | Q63021326 | ||
| Matthew T Roe | Q64684757 | ||
| P2093 | author name string | John S Rumsfeld | |
| P Michael Ho | |||
| Karen P Alexander | |||
| Thomas M Maddox | |||
| David Dai | |||
| John C Messenger | |||
| Brahmajee K Nallamothu | |||
| Thomas T Tsai | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal dialysis | Q202301 |
| contraindication | Q1848900 | ||
| P304 | page(s) | 2458-2464 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention | |
| P478 | volume | 302 |
| Q22241919 | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q38442992 | Anticoagulation in Chronic Hemodialysis: Progress Toward an Optimal Approach |
| Q44318647 | Bad kidneys are bad for the heart: but what can we do about it? |
| Q53150011 | Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). |
| Q90608305 | Care of Patients With Chronic Kidney Disease Presenting With Acute Coronary Syndrome: Improved, But Not Good Enough |
| Q34368413 | Contraindicated use of bevacizumab and toxicity in elderly patients with cancer |
| Q38527612 | Dialysis Facility Safety: Processes and Opportunities |
| Q30800602 | Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry |
| Q34716730 | Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. |
| Q37862264 | Enoxaparin: a pharmacologic and clinical review |
| Q22306356 | Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association |
| Q22241921 | Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association |
| Q30238784 | Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association |
| Q29547236 | Heart disease and stroke statistics--2011 update: a report from the American Heart Association |
| Q29547909 | Heart disease and stroke statistics--2012 update: a report from the American Heart Association |
| Q29547691 | Heart disease and stroke statistics--2014 update: a report from the American Heart Association |
| Q38364890 | How to balance risks and benefits in the management of CKD patients with coronary artery disease |
| Q95383264 | Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents |
| Q51341313 | Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention. |
| Q37968583 | Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention |
| Q59414744 | Medication errors in dialysis patients undergoing PCI |
| Q35586347 | Medication errors in patients with severe chronic kidney disease and acute coronary syndrome: the impact of computer-assisted decision support |
| Q43879938 | No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease. |
| Q26852002 | Patient and facility safety in hemodialysis: opportunities and strategies to develop a culture of safety |
| Q45784975 | Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines? |
| Q36021782 | Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease |
| Q36338328 | Quality and Outcomes of Treatment of Hypercalcemia of Malignancy |
| Q27694667 | Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis |
| Q48112185 | The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium. |
| Q48097465 | The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). |
| Q33432621 | Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program |
Search more.